MX366204B - Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular. - Google Patents

Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.

Info

Publication number
MX366204B
MX366204B MX2015014847A MX2015014847A MX366204B MX 366204 B MX366204 B MX 366204B MX 2015014847 A MX2015014847 A MX 2015014847A MX 2015014847 A MX2015014847 A MX 2015014847A MX 366204 B MX366204 B MX 366204B
Authority
MX
Mexico
Prior art keywords
pathway
wnt
prediction
signalling pathway
treatment response
Prior art date
Application number
MX2015014847A
Other languages
English (en)
Other versions
MX2015014847A (es
Inventor
Jan Van Ooijen Hendrik
Franciscus Johannes Verhaegh Wilhelmus
Van De Stolpe Anja
Alves De Inda Màrcia
Original Assignee
Koninklijke Philips Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips Nv filed Critical Koninklijke Philips Nv
Publication of MX2015014847A publication Critical patent/MX2015014847A/es
Publication of MX366204B publication Critical patent/MX366204B/es

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Probability & Statistics with Applications (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)

Abstract

La presente invención se refiere a un método para determinar una puntuación del riesgo que indica un riesgo de que un evento clínico ocurrirá dentro de un cierto período de tiempo. La puntuación del riesgo se basa al menos en parte en una combinación de actividades inferidas de dos o más trayectorias de señalización celular en un tejido y/o células y/o fluido corporal de un sujeto. Las trayectorias de señalización celular comprenden una trayectoria Wnt, una trayectoria ER, una trayectoria HH, y/o una trayectoria AR. La puntuación del riesgo se define de tal forma que el riesgo indicado de que ocurrirá un evento clínico dentro de un cierto período de tiempo se reduce con un PER en aumento y aumenta con un max (Pwnt, PHH) en aumento, en donde PER, Pwnt, y PHH denotan la actividad inferida de la trayectoria ER, la trayectoria Wnt, y la trayectoria HH, respectivamente.
MX2015014847A 2013-04-26 2014-04-24 Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular. MX366204B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165471 2013-04-26
PCT/EP2014/058326 WO2014174003A1 (en) 2013-04-26 2014-04-24 Medical prognosis and prediction of treatment response using multiple cellular signalling pathway activities

Publications (2)

Publication Number Publication Date
MX2015014847A MX2015014847A (es) 2016-03-11
MX366204B true MX366204B (es) 2019-07-02

Family

ID=48182831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014847A MX366204B (es) 2013-04-26 2014-04-24 Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.

Country Status (11)

Country Link
US (1) US11309059B2 (es)
EP (2) EP3372695B1 (es)
JP (1) JP6603208B2 (es)
KR (1) KR102256141B1 (es)
CN (1) CN105121665B (es)
AU (1) AU2014259459B2 (es)
BR (1) BR112015026736A2 (es)
CA (1) CA2909991A1 (es)
MX (1) MX366204B (es)
RU (1) RU2718647C2 (es)
WO (1) WO2014174003A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015026736A2 (pt) 2013-04-26 2017-07-25 Koninklijke Philips Nv método, aparelho, mídia de armazenamento não transitório, programa de computador, e, sinal
AU2014375206B2 (en) 2014-01-03 2021-09-30 Innosign B.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US11610644B2 (en) 2014-10-24 2023-03-21 Koninklijke Philips N.V. Superior bioinformatics process for identifying at risk subject populations
CN107077536B (zh) 2014-10-24 2021-09-28 皇家飞利浦有限公司 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性
CA2995520A1 (en) 2015-08-14 2017-02-23 Hendrik Jan VAN OOIJEN Assessment of nfkb cellular signaling pathway activity using mathematical modelling of target gene expression
US20190128899A1 (en) * 2016-06-13 2019-05-02 Koninklijke Philips N.V. Method for inferring activity of a transcription factor of a signal transduction pathway in a subject
WO2018152240A1 (en) * 2017-02-14 2018-08-23 The Regents Of The University Of Colorado, A Body Corporate Methods for predicting transcription factor activity
EP3431582A1 (en) 2017-07-18 2019-01-23 Koninklijke Philips N.V. Cell culturing materials
BR112020006605A2 (pt) 2017-10-02 2020-10-06 Koninklijke Philips N.V. método para determinar o status funcional de ao menos um tipo de célula imune em ao menos uma amostra de um indivíduo, método para determinar o status de atividade do sistema imune inato ou adaptativo de um indivíduo, método para determinar o status de atividade do sistema imune global de um indivíduo, aparelho, mídia de armazenamento não transitório, programa de computador e kit
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
CN113316823A (zh) * 2018-09-29 2021-08-27 豪夫迈·罗氏有限公司 基于多模态机器学习的临床预测器
EP3963108A1 (en) * 2019-05-03 2022-03-09 Koninklijke Philips N.V. Methods of prognosis in high-grade serous ovarian cancer
EP3739588A1 (en) 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
WO2021022365A1 (en) * 2019-08-02 2021-02-11 Intellijoint Surgical Inc. Systems and methods to collaborate, to train an expert system and to provide an expert system
EP3882363A1 (en) 2020-03-17 2021-09-22 Koninklijke Philips N.V. Prognostic pathways for high risk sepsis patients
KR102565378B1 (ko) * 2020-03-23 2023-08-10 단국대학교 산학협력단 유방암 호르몬 수용체의 상태 예측을 위한 바이오 마커
EP4136261B1 (en) 2020-04-16 2025-04-02 InnoSIGN B.V. Prognostic pathways for viral infections
EP3978628A1 (en) 2020-10-01 2022-04-06 Koninklijke Philips N.V. Prognostic pathways for viral infections
EP3940704A1 (en) 2020-07-14 2022-01-19 Koninklijke Philips N.V. Method for determining the differentiation state of a stem cell
EP3960875A1 (en) * 2020-08-28 2022-03-02 Koninklijke Philips N.V. Pcr method and kit for determining pathway activity
EP3965119A1 (en) 2020-09-04 2022-03-09 Koninklijke Philips N.V. Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices
EP3974540A1 (en) 2020-09-25 2022-03-30 Koninklijke Philips N.V. Method for predicting immunotherapy resistance
KR102189142B1 (ko) * 2020-10-15 2020-12-09 서울대학교병원 만성신장질환의 악화 예측 마커로서의 snp 및 이의 이용
EP4015651A1 (en) 2020-12-17 2022-06-22 Koninklijke Philips N.V. Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients
EP4039825A1 (en) 2021-02-09 2022-08-10 Koninklijke Philips N.V. Comparison and standardization of cell and tissue culture
KR20230155549A (ko) 2021-03-11 2023-11-10 코닌클리케 필립스 엔.브이. 고위험 패혈증 환자를 위한 예측 경로
CN114410667B (zh) * 2021-12-31 2022-10-11 广东省科学院动物研究所 一种鞍带石斑鱼znrf3基因及其编码的蛋白和应用
KR102508252B1 (ko) * 2022-01-11 2023-03-09 주식회사 볼츠만바이오 생체신호전달 네트워크 모델의 학습방법 및 이를 위한 장치
CN114524872A (zh) * 2022-03-09 2022-05-24 广州诺诚生物技术研发有限公司 一种用于乳腺癌检测的单克隆抗体及其试剂盒
CN120138048A (zh) * 2025-03-11 2025-06-13 河南师范大学 一种过表达yes1基因的质粒载体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235255A1 (en) 2005-04-15 2006-10-19 Gartside Robert J Double bond hydroisomerization process
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
RU2376372C2 (ru) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Способ генетической диагностики подверженности к сердечно-сосудистым заболеваниям
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
RU2013140708A (ru) * 2011-02-04 2015-03-10 Конинклейке Филипс Н.В. Способ для оценки потока информации в биологических сетях
EP2549399A1 (en) 2011-07-19 2013-01-23 Koninklijke Philips Electronics N.V. Assessment of Wnt pathway activity using probabilistic modeling of target gene expression
WO2013084144A1 (en) 2011-12-08 2013-06-13 Koninklijke Philips Electronics N.V. Semiconductor light emitting device with thick metal layers
US11306360B2 (en) 2012-12-26 2022-04-19 Koninklijke Philips N.V. Assessment of cellular signaling pathway activity using linear combination(s) of target gene expressions
BR112015026736A2 (pt) 2013-04-26 2017-07-25 Koninklijke Philips Nv método, aparelho, mídia de armazenamento não transitório, programa de computador, e, sinal

Also Published As

Publication number Publication date
CN105121665A (zh) 2015-12-02
EP2989211B1 (en) 2018-06-13
MX2015014847A (es) 2016-03-11
AU2014259459B2 (en) 2020-03-26
RU2718647C2 (ru) 2020-04-10
US20160110494A1 (en) 2016-04-21
US11309059B2 (en) 2022-04-19
AU2014259459A1 (en) 2015-12-17
CN105121665B (zh) 2019-11-26
BR112015026736A2 (pt) 2017-07-25
CA2909991A1 (en) 2014-10-30
WO2014174003A1 (en) 2014-10-30
KR20160003124A (ko) 2016-01-08
EP3372695B1 (en) 2020-09-09
RU2015150464A (ru) 2017-06-02
EP3372695A1 (en) 2018-09-12
JP6603208B2 (ja) 2019-11-06
KR102256141B1 (ko) 2021-05-27
JP2016519926A (ja) 2016-07-11
EP2989211A1 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
MX2015014847A (es) Pronostico medico y prediccion de la respuesta al tratamiento utilizando multiples actividades de la trayectoria de señalizacion celular.
Galama et al. Grossman’s missing health threshold
MX2016004899A (es) Metodos para evaluar el desarrollo de bebes y niños via rastreo ocular.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
HK1205964A1 (en) Kit and devices for organ perfusion
EP4601278A3 (en) System and device of dynamic glucose profile response to physiological parameters
WO2014152754A3 (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
GEP20166449B (en) Treatment of pain associated with dislocation of basal endometrium
HK1209035A1 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
HK1220520A1 (zh) 预测对疼痛治疗的应答的方法和系统
WO2014125378A3 (en) Systems and methods for managing and dynamically predicting respiratory episodes
WO2014159926A3 (en) Medical treatment management
WO2015067710A3 (en) Tyrp1, a natural mirna sponge, and its use in managing human melanoma aggressiveness
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
MX378093B (es) Composiciones para usarse en el tratamiento de linfoma cutáneo de células t.
IL223544A (en) System and method for determining by an external entity the human hierarchial structure of an organization. using public social networks
BR112014019274A2 (pt) métodos relacionados ao tratamento de doenças e distúrbios inflamatórios
WO2014179487A3 (en) Health care communications management system and method of use
UA45411U (ru) Способ прогнозирования тяжести течения лептоспироза
UA86357U (ru) Способ прогнозирования эффективности лечения больных с синдромом сухого глаза на фоне поствариэктомического синдрома
UA99717U (uk) Спосіб прогнозування досягнення цільового артеріального тиску у хворих з артеріальною гіпертензією та цукровим діабетом
Shimokawaji et al. Pre-Treatment With Clarithromycin Modulates LPS-Stimulated IL-8 Secretion In Association With Modulation Of IL-8 MRNA And ERK In Normal Human Bronchial Epithelial Cells
UA83553U (ru) Способ прогнозирования развития рецидивирующего течения пиелонефрита
WO2018222432A8 (en) A predictive biomarker for let-7 microrna-based therapeutics for the treatment of human cancer
UA107904U (uk) Спосіб контролю за ефективністю терапії у хворих на запальні артропатії з супутніми захворюваннями

Legal Events

Date Code Title Description
FG Grant or registration